Modeling the structure and DAP5-binding site of the FGF-9 5′-UTR RNA utilized in cap-independent translation

  1. Dixie J. Goss
  1. PhD Program in Biochemistry, The Graduate Center, CUNY, New York, New York 10016, USA
  2. Department of Chemistry, Hunter College, CUNY, New York, New York 10065, USA
  1. Corresponding author: dgoss{at}hunter.cuny.edu
  1. Handling editor: Adrian Ferre-D'Amare

Abstract

Cap-independent or eukaryotic initiation factor (eIF) 4E-independent, translation initiation in eukaryotes requires scaffolding protein eIF4G or its homolog, death-associated protein 5 (DAP5). eIF4G associates with the 40S ribosomal subunit, recruiting the ribosome to the RNA transcript. A subset of RNA transcripts, such as fibroblast growth factor 9 (FGF-9), contain 5′ untranslated regions (5′ UTRs) that directly bind DAP5 or eIF4GI. For viral mRNA, eIF recruitment usually utilizes RNA structure, such as a pseudoknot or stem–loops, and the RNA-helicase eIF4A is required for DAP5- or 4G-mediated translation, suggesting these 5′ UTRs are structured. However, for cellular IRES-like translation, no consensus RNA structures or sequences have yet been identified for eIF binding. However, the DAP5-binding site within the FGF-9 5′ UTR is unknown. Moreover, DAP5 binds to other, dissimilar 5′ UTRs, some of which require an unpaired, accessible 5′ end to stimulate cap-independent translation. Using SHAPE-seq, we modeled the 186 nt FGF-9 5′-UTR RNA's complex secondary structure in vitro. Further, DAP5 footprinting, toeprinting, and UV cross-linking experiments identify DAP5–RNA interactions. Modeling of FGF-9 5′-UTR tertiary structure aligns DAP5-interacting nucleotides on one face of the predicted structure. We propose that RNA structure involving tertiary folding, rather than a conserved sequence or secondary structure, acts as a DAP5-binding site. DAP5 appears to contact nucleotides near the start codon. Our findings offer a new perspective in the hunt for cap-independent translational enhancers. Structural, rather than sequence-specific, eIF-binding sites may act as attractive chemotherapeutic targets or as dosage tools for mRNA-based therapies.

Keywords

  • Received February 28, 2024.
  • Accepted May 28, 2024.

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents